Faculty Collaboration Database

Medical College of Wisconsin

CTSI Research Informatics REDCap

Binod Dhakal MBBS, MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Member of the Cancer Center

Send Message

Request Meeting

View Curriculum Vitae

Publications (192)

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series. (Susanibar-Adaniya S, Derman BA, Cohen AD, Vogl DT, Richard S, Rossi A, Frigualt MJ, Yee AJ, Dhakal B, Bar N) Blood Cancer J 2026 Apr 28;16(1) PMID: 42049698 PMCID: PMC13125467 SCOPUS ID: 2-s2.0-105037218527 04/29/2026

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference. (Chari A, Costello C, Krishnan A, Patel K, Banerjee R, Berdeja JG, Biran N, Callander N, Costa LJ, Dhakal B, Gasparetto C, Hansen DK, Kumar A, Nooka AK, Pan D, Richard S) Am J Hematol 2026 Apr 21 PMID: 42014940 SCOPUS ID: 2-s2.0-105036161877 04/22/2026

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. (Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK) Blood Cancer J 2026 Apr 14 PMID: 41980929 04/15/2026

Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection. (Al Hadidi S, Costello C, Costa LJ, Dhakal B, Georges P, Gajra A, Lin Y, Bhargava RS, Paner-Straseviciute A, Vij R) Clin Lymphoma Myeloma Leuk 2026 Mar 17 PMID: 41936482 SCOPUS ID: 2-s2.0-105034792249 04/06/2026

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study. (Dhakal B, Levy MY, Ko G, He J, Kim N, Tang W, Le Blanc T, Fowler J, Lucht S, Brown M, Bland E, Craig C, Giegerich S, Laney J, Feinberg B, Gupta-Werner N, Kaila S, Voorhees P) Oncol Ther 2026 Mar 26 PMID: 41886245 SCOPUS ID: 2-s2.0-105034419682 03/26/2026

FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA. (Ailawadhi S, Hansen DK, Dhakal B, Shune LO, Anderson LD Jr, De Braganca KC, Lengil T, Alegria V, Perciavalle M, Lu JH, Sacchi E, Lee S, Emond B, Huo S, Bixby T, Qureshi ZP, Sborov DW) Adv Ther 2026 Mar 24 PMID: 41874852 SCOPUS ID: 2-s2.0-105034404819 03/24/2026

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. (Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ) Blood Cancer J 2026 Mar 20;16(1) PMID: 41862439 PMCID: PMC13018517 SCOPUS ID: 2-s2.0-105033651563 03/21/2026

Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma. (Aughey E, Estrada-Merly N, Akhtar OS, Dhakal B, Mohan M, Narra R, Pasquini MC, D'Souza A) Br J Haematol 2026 Mar 09 PMID: 41797476 SCOPUS ID: 2-s2.0-105032145910 03/09/2026

Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability. (Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock R) Blood Adv 2026 Feb 24;10(4):1400-1404 PMID: 41733946 SCOPUS ID: 2-s2.0-105030120191 02/24/2026

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant. (Venkatesh P, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ, Bal S) Br J Haematol 2026 Mar;208(3):1001-1008 PMID: 41693283 SCOPUS ID: 2-s2.0-105030173566 02/16/2026

Fine Mapping of MHC Region Identifies Novel Susceptibility Loci in Multiple Myeloma When Comparing With Its Precursor Monoclonal Gammopathy of Unknown Significance. (Arsang-Jang S, Massat B, Pareek G, Han J, Thapa B, Patek V, Nader Z, Auer PL, Zimmerman MT, Urrutia R, Hari P, D'Souza A, Dhakal B, Janz S, Dong J) HLA 2026 Feb;107(2):e70589 PMID: 41685425 PMCID: PMC12902906 SCOPUS ID: 2-s2.0-105029925738 02/13/2026

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy. (Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Giri S, Godby KN, Silbermann RW, Mikhail FM, Huls F, Reddy V, Costa LJ) Blood 2026 Apr 16;147(16):1857-1862 PMID: 41592281 SCOPUS ID: 2-s2.0-105033982851 01/27/2026 1 Citation

Implementation of Bispecific Antibodies in the Community: Lessons From the ThedaCare Cancer Center Experience. (Zhou K, Ebben L, Dhakal B, Vallatharasu Y) JCO Oncol Pract 2026 Jan 13:OP2500748 PMID: 41529233 SCOPUS ID: 2-s2.0-105032026315 01/13/2026

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. (Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martínez-López J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R) Lancet Oncol 2026 Feb;27(2):254-268 PMID: 41519141 SCOPUS ID: 2-s2.0-105029011095 01/11/2026 4 Citations

Translocation t(11;14) and BCL2-inhibition in multiple myeloma. (Sim S, Dhakal B, Quach H) Haematologica 2025 Dec 24 PMID: 41437818 12/24/2025

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. (Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y, Annyapu E, Dhakal B, Bhutani D, Thanendrarajan S, Zangari M, D'Souza A, Lentzsch S, van Rhee F, Chakraborty R, Schinke C, Mohan M, Shah MR) Blood Cancer J 2025 Nov 07;15(1):196 PMID: 41203605 PMCID: PMC12594773 SCOPUS ID: 2-s2.0-105021068508 11/08/2025 3 Citations

Mindfulness vs. sleep education during autologous hematopoietic cell transplantation for multiple myeloma: Feasibility of a randomized controlled pilot study (Henley EC, Liphart HA, Morris KJ, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D'Souza A, Stolley M, Dhakal B, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Bendis PC, Rentscher KE, Rumble ME, Szabo A, Rao S, Knight JM) Contemporary Clinical Trials Communications October 2025;47 SCOPUS ID: 2-s2.0-105013637528 10/01/2025

Mindfulness vs. sleep education during autologous hematopoietic cell transplantation for multiple myeloma: Feasibility of a randomized controlled pilot study. (Henley EC, Liphart HA, Morris KJ, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D'Souza A, Stolley M, Dhakal B, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Bendis PC, Rentscher KE, Rumble ME, Szabo A, Rao S, Knight JM) Contemp Clin Trials Commun 2025 Oct;47:101540 PMID: 40893725 PMCID: PMC12397865 SCOPUS ID: 2-s2.0-105013637528 09/02/2025

Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. (Ailawadhi S, Anderson LD Jr, Dhakal B, Shune L, Sborov DW, Hansen DK) Clin Lymphoma Myeloma Leuk 2026 Feb;26(2):85-93 PMID: 40885679 SCOPUS ID: 2-s2.0-105014729212 08/31/2025 3 Citations

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. (Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW) Blood Adv 2025 Dec 09;9(23):6009-6018 PMID: 40875887 PMCID: PMC12686786 SCOPUS ID: 2-s2.0-105024244013 08/28/2025 2 Citations

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis. (Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D'Souza A, Pasquini M, Dhakal B) Haematologica 2026 Feb 01;111(2):745-750 PMID: 40820831 PMCID: PMC12862333 SCOPUS ID: 2-s2.0-105029263293 08/18/2025

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma. (Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J, Lee S, Lonardi C, Slaughter A, Lendvai N, Schecter JM, Chen D, Zhao M, Yeh TM, Leleu X, Puig N, Dytfeld D, Zamagni E, Weisel K, Karlin L, Delforge M, Corradini P, Mina R, Roeloffzen W, Sidana S) Adv Ther 2025 Oct;42(10):5023-5041 PMID: 40768190 PMCID: PMC12474644 SCOPUS ID: 2-s2.0-105012841831 08/06/2025 1 Citation

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. (Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees M, Costello P, Vazquez Martinez M, Pasvolsky O, Wagner C, Davis JA, Castaneda Puglianini O, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo R, Freeman C, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa M, Midha S, Alsina M, Sborov D, Patel K, Lin Y, Ferreri C, Gagelmann N, Kumar A, Hansen D, Cowan A, Costa LJ, Merz M, Sidana S) Blood 2025 Oct 23;146(17):2063-2072 PMID: 40749169 SCOPUS ID: 2-s2.0-105014970046 08/01/2025 15 Citations

Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database. (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, Varghese NE, He J, Kharat A, Lee S, Cost P, Potluri R, Koneru M, Patel N, Florendo E, Rodriguez-Otero P, Yong K) Cancer Med 2025 Aug;14(15):e71093 PMID: 40719208 PMCID: PMC12301936 SCOPUS ID: 2-s2.0-105011846353 07/28/2025

Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. (Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin GR) Leukemia 2025 Sep;39(9):2289-2291 PMID: 40670671 SCOPUS ID: 2-s2.0-105011037613 07/17/2025

Molecular and immunological determinants of long-term survival in multiple myeloma. (Kasomva K, Yadav K, Janz S, Dhakal B, Rao S) Blood Adv 2025 Oct 28;9(20):5134-5147 PMID: 40674709 PMCID: PMC12550235 SCOPUS ID: 2-s2.0-105022754796 07/17/2025 1 Citation

The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia. (Shrestha A, Thanendrarajan S, Bag A, Dhakal B, Zangari M, Al-Hadidi S, van Rhee F, D'Souza A, Shah N, Shah MR, Mohan M, Schinke C) Blood Adv 2025 Oct 14;9(19):4806-4809 PMID: 40674710 PMCID: PMC12494909 SCOPUS ID: 2-s2.0-105017267704 07/17/2025 1 Citation

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. (Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM) J Clin Oncol 2025 Sep;43(25):2766-2771 PMID: 40459151 PMCID: PMC12393059 SCOPUS ID: 2-s2.0-105007057385 06/03/2025 61 Citations

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. (Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D'Souza A, Shah N, Chakraborty R, Shah MR, Schinke C) Blood Cancer J 2025 Apr 23;15(1):74 PMID: 40268898 PMCID: PMC12018942 SCOPUS ID: 2-s2.0-105003139880 04/24/2025 24 Citations

Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy. (Bal S, Magnusson T, Ravi G, Giri S, Godby K, Dhakal B, Callander NS, Silbermann RW, Dholaria B, Reddy VB, Costa LJ) Blood Cancer J 2025 Apr 23;15(1):73 PMID: 40268941 PMCID: PMC12019237 SCOPUS ID: 2-s2.0-105003126302 04/24/2025 1 Citation

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. (Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, Vesole DH, Nooka A, Paul B, Hari PN, D'Ambrosi S, Kuiper R, van Vliet M, Siegel D, Usmani SZ, van Rhee F) Br J Haematol 2025 Jun;206(6):1642-1653 PMID: 40231946 SCOPUS ID: 2-s2.0-105002595395 04/15/2025 5 Citations

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. (Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman CL, Afrough A, Anderson LD Jr, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau H, Mirza AS, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini MC) Blood 2025 Jul 10;146(2):167-177 PMID: 40198886 PMCID: PMC12964216 SCOPUS ID: 2-s2.0-105004741731 04/09/2025 14 Citations

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. (Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria BR, Bal S, Ravi G, Chhabra S, Silbermann RW, Costa L) Blood 2025 Aug 07;146(6):707-716 PMID: 40193714 SCOPUS ID: 2-s2.0-105006948795 04/07/2025 10 Citations

Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. (Chari A, Bal S, Ailawadhi S, Krishnan A, Patel KK, Berdeja JG, Garfall A, Callander N, Banerjee R, Alsina M, Nooka AK, Dhakal B, Gasparetto C, Costello C) Clin Lymphoma Myeloma Leuk 2025 Sep;25(9):635-645 PMID: 40175263 SCOPUS ID: 2-s2.0-105001849375 04/03/2025 3 Citations

Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable. (Alsina M, Dhakal B, Pantin J, Huff CA, Janakiram M) Future Oncol 2025 Apr;21(10):1137-1144 PMID: 40098471 PMCID: PMC11988239 SCOPUS ID: 2-s2.0-105000821564 03/18/2025 3 Citations

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. (Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Bhurtel E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G) Blood Adv 2025 May 13;9(9):2336-2340 PMID: 40088469 PMCID: PMC12127628 SCOPUS ID: 2-s2.0-105005798542 03/16/2025

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S, US Multiple Myeloma Immunotherapy Consortium) J Clin Oncol 2025 Apr 10;43(11):1399 PMID: 40053892 SCOPUS ID: 2-s2.0-105003036760 03/07/2025 1 Citation

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database. (Dhakal B, He J, Schecter JM, Deraedt W, Slaughter A, Lonardi C, Nair S, He J, Lee S, Cost P, Patel N, Koneru M, Einsele H) Clin Lymphoma Myeloma Leuk 2025 Jun;25(6):e394-e403 PMID: 39966019 SCOPUS ID: 2-s2.0-85217889094 02/19/2025 7 Citations

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. (Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S, US Multiple Myeloma Immunotherapy Consortium) J Clin Oncol 2025 May;43(13):1597-1609 PMID: 39965175 PMCID: PMC12037312 SCOPUS ID: 2-s2.0-85218769357 02/18/2025 28 Citations

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy. (Costa LJ, Medvedova E, Dhakal B, Dholaria BR, Godby KN, Bal S, Ravi G, Giri S, Chhabra S, Silbermann R, Callander NS) Blood Cancer J 2025 Feb 05;15(1):13 PMID: 39910064 PMCID: PMC11799218 SCOPUS ID: 2-s2.0-85218257122 02/06/2025 3 Citations

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings. (Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC Jr, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B) Front Immunol 2024;15:1369619 PMID: 39906744 PMCID: PMC11791645 SCOPUS ID: 2-s2.0-85216792148 02/05/2025 3 Citations

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. (Dhakal B, Hari P, Chhabra S, Szabo A, Lum LG, Glass DD, Park JH, Donato M, Siegel DS, Felizardo TC, Fowler DH) J Immunother Cancer 2025 Jan 28;13(1) PMID: 39875173 PMCID: PMC11781102 SCOPUS ID: 2-s2.0-85216937952 01/29/2025

Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. (Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen D, Ferreri C, Dhakal B, Dhanda D, Harrison M, Kitali A, Landau H, Mirza AS, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Gowda L, Anderson LD Jr, Pasquini MC, Usmani S, Freeman CL) Blood Adv 2025 Apr 08;9(7):1587-1592 PMID: 39786391 PMCID: PMC11986210 SCOPUS ID: 2-s2.0-105002032521 01/09/2025 4 Citations

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells. (Narra RK, Peshin S, Dhakal B) Acta Haematol 2025;148(3):330-345 PMID: 39733769 SCOPUS ID: 2-s2.0-85217540324 12/30/2024 4 Citations

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. (Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B) Eur J Cancer 2025 Jan 17;215:115157 PMID: 39673835 SCOPUS ID: 2-s2.0-85211582731 12/15/2024 6 Citations

Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. (Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS) Br J Haematol 2024 Dec;205(6):2370-2375 PMID: 39396814 PMCID: PMC12714362 SCOPUS ID: 2-s2.0-85206072300 10/14/2024 4 Citations

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. (Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK) Blood 2025 Jan 02;145(1):85-97 PMID: 39365257 PMCID: PMC11952008 SCOPUS ID: 2-s2.0-85209775564 10/04/2024 101 Citations

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. (Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D) Clin Cancer Res 2024 Oct 01;30(19):4542 PMID: 39350638 PMCID: PMC11443237 SCOPUS ID: 2-s2.0-85205446162 10/01/2024 2 Citations

Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M) Transplant Cell Ther 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 PMCID: PMC12483827 SCOPUS ID: 2-s2.0-85206435293 09/21/2024 3 Citations

Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center. (Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A) Transplant Cell Ther 2024 Dec;30(12):1189.e1-1189.e10 PMID: 39277111 PMCID: PMC11736859 SCOPUS ID: 2-s2.0-85205846893 09/15/2024 4 Citations

Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. (Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M) Br J Haematol 2024 Nov;205(5):1830-1834 PMID: 39192546 SCOPUS ID: 2-s2.0-85202177578 08/28/2024 3 Citations

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers. (Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, Le HH, DeBrosse A, Okorozo P, McDowell R, Patel S, Bunn J, Hawks K, Zhang X, Rodriguez C) Curr Med Res Opin 2024 Oct;40(10):1705-1711 PMID: 39177290 SCOPUS ID: 2-s2.0-85201809794 08/23/2024 9 Citations

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. (Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M) Blood Cancer J 2024 Aug 12;14(1):137 PMID: 39134535 PMCID: PMC11319778 SCOPUS ID: 2-s2.0-85201250452 08/13/2024 15 Citations

Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. (San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H) Future Oncol 2024;20(33):2509-2520 PMID: 39110421 PMCID: PMC11537292 SCOPUS ID: 2-s2.0-85200761365 08/07/2024 1 Citation

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong K) Blood Adv 2024 Oct 08;8(19):5062-5071 PMID: 39110988 PMCID: PMC11459902 SCOPUS ID: 2-s2.0-85206247561 08/07/2024 13 Citations

Safety of Dapsone for Pneumocystis Jiroveci Pneumonia Prophylaxis in Patients With Multiple Myeloma. (Kim M, Arabi J, McCoy C, D'Souza A, Chhabra S, Abid MB, Thapa B, Dhakal B) Clin Lymphoma Myeloma Leuk 2024 Nov;24(11):804-807 PMID: 39043500 SCOPUS ID: 2-s2.0-85200365330 07/24/2024

Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. (Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK) Front Immunol 2024;15:1405452 PMID: 38915401 PMCID: PMC11194690 SCOPUS ID: 2-s2.0-85196643451 06/25/2024 5 Citations

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M) Blood Adv 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024 15 Citations

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. (Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM) Blood Cancer J 2024 Apr 22;14(1):69 PMID: 38649340 PMCID: PMC11035596 SCOPUS ID: 2-s2.0-85191093548 04/23/2024 26 Citations

ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. (Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, Hamadani M, Dhakal B, Usmani SZ) Transplant Cell Ther 2024 Aug;30(8):750-759 PMID: 38615990 SCOPUS ID: 2-s2.0-85193954557 04/15/2024 3 Citations

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. (Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C) Blood Cancer J 2024 Mar 06;14(1):38 PMID: 38443358 PMCID: PMC10915134 SCOPUS ID: 2-s2.0-85186929795 03/06/2024 6 Citations

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. (Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R) Blood Cancer J 2024 Mar 05;14(1):35 PMID: 38443345 PMCID: PMC10914756 SCOPUS ID: 2-s2.0-85186867281 03/06/2024 78 Citations

Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. (Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C) Bone Marrow Transplant 2024 May;59(5):647-652 PMID: 38361116 SCOPUS ID: 2-s2.0-85185115608 02/16/2024 22 Citations

Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M) Bone Marrow Transplant 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024 6 Citations

Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. (Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M) Transplant Cell Ther 2024 Mar;30(3):285-297 PMID: 38142942 SCOPUS ID: 2-s2.0-85183537164 12/25/2023 12 Citations

Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B) Br J Haematol 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023 6 Citations

Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance. (Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J) Leukemia 2024 Feb;38(2):383-385 PMID: 37919604 PMCID: PMC11326531 SCOPUS ID: 2-s2.0-85175540732 11/03/2023 1 Citation

Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Anderson LD Jr, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, Perales MA, Pasquini MC) Transplant Cell Ther 2024 Jan;30(1):17-37 PMID: 37913909 PMCID: PMC10873054 SCOPUS ID: 2-s2.0-85179661316 11/02/2023 39 Citations

Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. (Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium) Bone Marrow Transplant 2024 Jan;59(1):121-124 PMID: 37803198 SCOPUS ID: 2-s2.0-85173730029 10/07/2023 2 Citations

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) Lancet Haematol 2023 Nov;10(11):e890-e901 PMID: 37776872 PMCID: PMC10836587 SCOPUS ID: 2-s2.0-85173823660 10/01/2023 136 Citations

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. (Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S) Clin Lymphoma Myeloma Leuk 2023 Dec;23(12):882-888 PMID: 37716872 SCOPUS ID: 2-s2.0-85171348317 09/17/2023 11 Citations

The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. (Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C) Haematologica 2024 Mar 01;109(3):906-914 PMID: 37646658 PMCID: PMC10905074 SCOPUS ID: 2-s2.0-85178101970 08/30/2023 48 Citations

Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation. (Silbermann RW, Schmidt TM, Bal S, Dhakal B, Dholaria B, Biltibo E, Chhabra S, Giri S, Godby KN, Gowda S, Medvedova E, Cornell RF, Callander NS, Costa LJ) EJHaem 2023 Aug;4(3):775-778 PMID: 37601885 PMCID: PMC10435700 08/21/2023

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting. (Wu JF, Dhakal B) J Hematol Oncol 2023 Jul 28;16(1):86 PMID: 37507805 PMCID: PMC10385907 SCOPUS ID: 2-s2.0-85166000641 07/29/2023 16 Citations

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. (Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D) Clin Cancer Res 2023 Dec 01;29(23):4784-4796 PMID: 37463058 PMCID: PMC10690096 SCOPUS ID: 2-s2.0-85178651085 07/18/2023 25 Citations

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. (Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M) Transplant Cell Ther 2023 Oct;29(10):594-597 PMID: 37422194 SCOPUS ID: 2-s2.0-85166329205 07/09/2023 43 Citations

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H) N Engl J Med 2023 Jul 27;389(4):335-347 PMID: 37272512 06/05/2023

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. (Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S) Cancer 2023 Jul 15;129(14):2179-2191 PMID: 37021929 PMCID: PMC10516285 SCOPUS ID: 2-s2.0-85151948699 04/07/2023 6 Citations

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. (Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K) Blood Adv 2023 Sep 26;7(18):5549-5553 PMID: 36724511 PMCID: PMC10514068 SCOPUS ID: 2-s2.0-85164933174 02/02/2023 2 Citations

Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. (Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, Htut M, Shah N, Wong SW, Sidana S, Cowan AJ, Alsina M, Cohen A, Holstein SA, Bergsagel L, Ailawadhi S, Raje N, Dhakal B, Rossi A, Lin Y) Transplant Cell Ther 2023 Apr;29(4):255-258 PMID: 36681151 PMCID: PMC10040426 SCOPUS ID: 2-s2.0-85148359214 01/22/2023 51 Citations

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. (Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M) Haematologica 2023 Aug 01;108(8):2249-2254 PMID: 36601982 PMCID: PMC10388259 SCOPUS ID: 2-s2.0-85166385557 01/06/2023 5 Citations

Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. (Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M) Bone Marrow Transplant 2023 Apr;58(4):443-445 PMID: 36550200 SCOPUS ID: 2-s2.0-85144572498 12/23/2022 20 Citations

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. (Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM) Transplant Cell Ther 2023 Mar;29(3):174.e1-174.e10 PMID: 36494017 SCOPUS ID: 2-s2.0-85146134468 12/10/2022 54 Citations

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. (Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M) JAMA Netw Open 2022 Oct 03;5(10):e2238961 PMID: 36306135 PMCID: PMC9617177 SCOPUS ID: 2-s2.0-85141003728 10/29/2022 36 Citations

Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. (Hodge A, Sheean P, O'Connor P, Tyler K, Kerschner A, Williams A, Jensik K, Visotcky A, D'Souza A, Hari P, Dhakal B, Chhabra S, Flynn KE, Hagen P, Stolley M) Support Care Cancer 2022 Dec;30(12):9771-9779 PMID: 36287278 SCOPUS ID: 2-s2.0-85140591976 10/27/2022 5 Citations

Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplant Cell Ther 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022

Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)] (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplantation and Cellular Therapy October 2022;28(10):717 SCOPUS ID: 2-s2.0-85101258094 10/01/2022

Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. (Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C) Am J Hematol 2022 Dec;97(12):E451-E453 PMID: 36097868 SCOPUS ID: 2-s2.0-85139019826 09/14/2022 13 Citations

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):863-868 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022 12 Citations

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. (Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, Chhabra S, Medvedova E, Godby KN, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS, Costa LJ) Am J Hematol 2022 Sep;97(9):1170-1177 PMID: 35731911 SCOPUS ID: 2-s2.0-85133435905 06/23/2022 7 Citations

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. (Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J) Blood Cancer J 2022 May 25;12(5):82 PMID: 35614050 PMCID: PMC9132975 SCOPUS ID: 2-s2.0-85130720530 05/26/2022 9 Citations

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. (Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr., Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A) Blood Adv 2022 Jul 12;6(13):3991-3995 PMID: 35507742 PMCID: PMC9278304 SCOPUS ID: 2-s2.0-85134538302 05/05/2022 9 Citations

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. (Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C) Am J Hematol 2022 Jul;97(7):E276-E280 PMID: 35472167 PMCID: PMC10476149 SCOPUS ID: 2-s2.0-85129190892 04/27/2022 5 Citations

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. (Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM) Yale J Biol Med 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022 5 Citations

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. (Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S) Transplant Cell Ther 2022 Jun;28(6):284-293 PMID: 35306217 SCOPUS ID: 2-s2.0-85128352615 03/21/2022 33 Citations

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. (Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P) Blood Cancer J 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 02/26/2022 41 Citations

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. (Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M) Cancer Cell 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022 41 Citations

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. (Dhakal B, Sharma S, Balcioglu M, Shchegrova S, Malhotra M, Zimmermann B, Billings PR, Harrington A, Sethi H, Aleshin A, Hari PN) Front Oncol 2022;12:786451 PMID: 35186734 PMCID: PMC8848740 SCOPUS ID: 2-s2.0-85124893548 02/22/2022 21 Citations

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS) Clin Lymphoma Myeloma Leuk 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022 3 Citations

Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. (Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A) Mol Cancer Ther 2022 Apr 01;21(4):502-510 PMID: 35086951 PMCID: PMC8983490 SCOPUS ID: 2-s2.0-85128145497 01/29/2022 7 Citations

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. (Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P) Blood Adv 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021 55 Citations

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) J Clin Oncol 2022 Sep 01;40(25):2901-2912 PMID: 34898239 SCOPUS ID: 2-s2.0-85137134934 12/14/2021 213 Citations

Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. (Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A) Transplant Cell Ther 2022 Feb;28(2):83.e1-83.e9 PMID: 34781066 PMCID: PMC8900987 SCOPUS ID: 2-s2.0-85121149797 11/16/2021 20 Citations

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. (Dhakal B, Chhabra S, Savani BN, Hamadani M) Br J Haematol 2022 Apr;197(1):28-40 PMID: 34671973 SCOPUS ID: 2-s2.0-85117396384 10/22/2021 13 Citations

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. (Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B) Cells 2021 Aug 02;10(8) PMID: 34440730 PMCID: PMC8391934 SCOPUS ID: 2-s2.0-85115041797 08/28/2021 28 Citations

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. (Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M) Blood 2021 Oct 07;138(14):1278-1281 PMID: 34339501 PMCID: PMC8332674 SCOPUS ID: 2-s2.0-85114112109 08/03/2021 107 Citations

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021 5 Citations

Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. (Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A) Leuk Res 2021 Oct;109:106648 PMID: 34182226 SCOPUS ID: 2-s2.0-85109506946 06/29/2021

Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. (Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S) Front Immunol 2021;12:667054 PMID: 34149703 PMCID: PMC8206561 SCOPUS ID: 2-s2.0-85108140164 06/22/2021 6 Citations

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2021 Jul;35(7):2141 PMID: 34091601 SCOPUS ID: 2-s2.0-85107532822 06/07/2021 1 Citation

Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. (Mohan M, Hari P, Dhakal B) JCO Oncol Pract 2021 Jul;17(7):405-413 PMID: 34003675 SCOPUS ID: 2-s2.0-85111055909 05/19/2021 19 Citations

KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. (Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF) Clin Lymphoma Myeloma Leuk 2021 Aug;21(8):526-535 PMID: 33985931 SCOPUS ID: 2-s2.0-85105544057 05/15/2021 21 Citations

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial (Noa Biran, Binod Dhakal, Suzanne Lentzsch, David Siegel, Saad Z. Usmani, Adriana Rossi, Cara Rosenbaum, Divaya Bhutani, David H. Vesole, Cesar Rodriguez, Ajay K. Nooka, Frits van Rhee, Lisette Stork-Sloots, Femke de Snoo, Pritish K. Bhattacharyya, Durga Prasad Dash, Sena Zümrütçü, Martin H. van Vliet, Parameswaran Hari, Ruben Niesvizky) eJHaem 05/11/2021

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. (Biran N, Dhakal B, Lentzsch S, Siegel D, Usmani SZ, Rossi A, Rosenbaum C, Bhutani D, Vesole DH, Rodriguez C, Nooka AK, van Rhee F, Stork-Sloots L, de Snoo F, Bhattacharyya PK, Dash DP, Zümrütçü S, van Vliet MH, Hari P, Niesvizky R) EJHaem 2021 Aug;2(3):375-384 PMID: 35844693 PMCID: PMC9175784 05/11/2021

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2021 Jun;35(6):1828 PMID: 33782538 PMCID: PMC8188513 SCOPUS ID: 2-s2.0-85103400893 03/31/2021

Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis (Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B) Journal of Geriatric Oncology November 2020;11(8):1285-1292 SCOPUS ID: 2-s2.0-85085911696 11/01/2020 19 Citations

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. (Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P) Br J Haematol 2020 Nov;191(3):442-452 PMID: 33094839 PMCID: PMC7990054 SCOPUS ID: 2-s2.0-85088463591 10/24/2020 12 Citations

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. (Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A) Cancer 2021 Jan 01;127(1):82-92 PMID: 32966625 PMCID: PMC7736245 SCOPUS ID: 2-s2.0-85091313309 09/24/2020 23 Citations

Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. (Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon YT, Carlson KS, Nazha A, Saber W) Leuk Lymphoma 2021 Jan;62(1):229-233 PMID: 32924688 PMCID: PMC7939047 SCOPUS ID: 2-s2.0-85090933926 09/15/2020 1 Citation

Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2020 Dec;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020 5 Citations

Autonomic nervous system control of multiple myeloma. (Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S) Blood Rev 2021 Mar;46:100741 PMID: 32807576 PMCID: PMC7876165 SCOPUS ID: 2-s2.0-85089534779 08/19/2020 20 Citations

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. (Dhakal B, Hari PN, Usmani SZ, Hamadani M) Bone Marrow Transplant 2021 Jan;56(1):9-19 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020 26 Citations

Salvage second transplantation in relapsed multiple myeloma. (Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P) Leukemia 2021 Apr;35(4):1214-1217 PMID: 32747684 PMCID: PMC8020391 SCOPUS ID: 2-s2.0-85088870056 08/05/2020 24 Citations

Trends in the use of therapeutic plasma exchange in multiple myeloma (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) Journal of Clinical Apheresis 1 August 2020;35(4):307-315 SCOPUS ID: 2-s2.0-85086092696 08/01/2020 8 Citations

Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. (Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A) Bone Marrow Transplant 2021 Jan;56(1):225-231 PMID: 32732941 PMCID: PMC7855279 SCOPUS ID: 2-s2.0-85088830942 08/01/2020 46 Citations

Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020 22 Citations

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020 8 Citations

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. (D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN) EClinicalMedicine 2020 Jun;23:100361 PMID: 32529175 PMCID: PMC7280748 SCOPUS ID: 2-s2.0-85085967990 06/13/2020 32 Citations

Trends in the use of therapeutic plasma exchange in multiple myeloma. (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) J Clin Apher 2020 Aug;35(4):307-315 PMID: 32516865 SCOPUS ID: 2-s2.0-85086092696 06/10/2020 8 Citations

Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. (Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B) J Geriatr Oncol 2020 Nov;11(8):1285-1292 PMID: 32513568 PMCID: PMC8721742 SCOPUS ID: 2-s2.0-85085911696 06/10/2020 19 Citations

Multiple myeloma and COVID-19. (Dhakal B, D'Souza A, Chhabra S, Hari P) Leukemia 2020 Jul;34(7):1961-1963 PMID: 32475990 SCOPUS ID: 2-s2.0-85085898339 06/02/2020 29 Citations

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial (D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN) Eclinicalmedicine June 2020;23 SCOPUS ID: 2-s2.0-85085967990 06/01/2020 32 Citations

Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. (Bhasin B, Szabo A, Wu R, Saad ER, Hari P, Dhakal B, Chhabra S, D'Souza A) Clin Lymphoma Myeloma Leuk 2020 Aug;20(8):e468-e473 PMID: 32340914 PMCID: PMC7450520 SCOPUS ID: 2-s2.0-85083660475 04/29/2020 4 Citations

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A) Leukemia 2020 Dec;34(12):3338-3347 PMID: 32313109 PMCID: PMC7572530 SCOPUS ID: 2-s2.0-85083712292 04/22/2020 43 Citations

Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis: A Population-Based Study. (Dhakal B, Rein L, Szabo A, Padmanabhan A) Chest 2020 Sep;158(3):1172-1175 PMID: 32224075 PMCID: PMC7478227 SCOPUS ID: 2-s2.0-85088362878 04/01/2020 9 Citations

Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020 5 Citations

Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020 15 Citations

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020 49 Citations

Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020 18 Citations

The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. (Paner A, Patel P, Dhakal B) Blood Rev 2020 May;41:100643 PMID: 31818702 SCOPUS ID: 2-s2.0-85076252358 12/11/2019 38 Citations

An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019 3 Citations

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 Jul 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019 20 Citations

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019 3 Citations

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 Jul 03;2(7):e196476 PMID: 31276175 PMCID: PMC12124690 SCOPUS ID: 2-s2.0-85068511187 07/06/2019 17 Citations

Myeloma sleeper agent in myeloid disguise. (Dhakal B, Janz S) Blood 2019 Jul 04;134(1):3-4 PMID: 31273002 SCOPUS ID: 2-s2.0-85069268458 07/06/2019 2 Citations

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. (Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators) Lancet Oncol 2019 Jun;20(6):781-794 PMID: 31097405 SCOPUS ID: 2-s2.0-85067190733 05/18/2019 346 Citations

When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. (Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A) Clin Lymphoma Myeloma Leuk 2019 Jun;19(6):e251-e258 PMID: 30987953 SCOPUS ID: 2-s2.0-85064179757 04/17/2019 9 Citations

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019 26 Citations

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. (Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A) Hematol Oncol Stem Cell Ther 2019 Mar;12(1):10-14 PMID: 30879471 SCOPUS ID: 2-s2.0-85052754317 03/19/2019 30 Citations

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. (Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F) Leuk Lymphoma 2019 Oct;60(10):2558-2562 PMID: 30845856 PMCID: PMC7176050 SCOPUS ID: 2-s2.0-85062788299 03/09/2019 16 Citations

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. (Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P) Biol Blood Marrow Transplant 2019 Apr;25(4):683-688 PMID: 30579965 PMCID: PMC6453717 SCOPUS ID: 2-s2.0-85060511135 12/24/2018 25 Citations

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018 32 Citations

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. (Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW) Biol Blood Marrow Transplant 2019 May;25(5):921-931 PMID: 30537549 SCOPUS ID: 2-s2.0-85060298203 12/12/2018 25 Citations

Novel biomarkers in multiple myeloma. (Levin A, Hari P, Dhakal B) Transl Res 2018 Nov;201:49-59 PMID: 30301522 SCOPUS ID: 2-s2.0-85050195259 10/12/2018 36 Citations

Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study. (Bhandari S, Pandey RK, Dahal S, Shahreyar M, Dhakal B, Jha P, Venkatesan T, Saeian K) South Med J 2018 Oct;111(10):628-633 PMID: 30285271 SCOPUS ID: 2-s2.0-85054342035 10/05/2018 7 Citations

Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma-Reply. (Dhakal B, Szabo A, Hari P) JAMA Oncol 2018 Nov 01;4(11):1618 PMID: 30098154 SCOPUS ID: 2-s2.0-85052681406 08/12/2018 2 Citations

Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018 36 Citations

Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. (Podder V, Dhakal B, Shaik GUS, Sundar K, Sivapuram MS, Chattu VK, Biswas R) Healthcare (Basel) 2018 Jul 10;6(3) PMID: 29996517 PMCID: PMC6163835 SCOPUS ID: 2-s2.0-85063913178 07/13/2018 6 Citations

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018 34 Citations

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 Aug;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018 9 Citations

Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. (Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A) Lancet Haematol 2018 May;5(5):e220-e231 PMID: 29703336 PMCID: PMC6437775 SCOPUS ID: 2-s2.0-85046022775 04/29/2018 104 Citations

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. (D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P) Contemp Clin Trials Commun 2017 Dec;8:33-38 PMID: 29696194 PMCID: PMC5898504 SCOPUS ID: 2-s2.0-85027981960 04/27/2018 17 Citations

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 Aug;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018 43 Citations

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018 7 Citations

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 PMID: 29302684 PMCID: PMC5885822 SCOPUS ID: 2-s2.0-85045789349 01/06/2018 143 Citations

A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. (Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Dhakal B, Pierce B, Aster RH, Padmanabhan A) Chest 2017 Oct;152(4):e77-e80 PMID: 28991552 PMCID: PMC5812761 SCOPUS ID: 2-s2.0-85030692808 10/11/2017 19 Citations

Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection. (Bhandari S, Mohammed Abdul MK, Dhakal B, Kreuziger LB, Saeian K, Stein D) Inflamm Bowel Dis 2017 Oct;23(10):1847-1852 PMID: 28837518 SCOPUS ID: 2-s2.0-85029761631 08/25/2017 21 Citations

Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017 4 Citations

IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. (Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, Dhakal B, Wen R, Wang D, Aster RH) Chest 2017 Sep;152(3):478-485 PMID: 28427966 PMCID: PMC5812774 SCOPUS ID: 2-s2.0-85028972116 04/22/2017 106 Citations

Marizomib for central nervous system-multiple myeloma. (Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P) Br J Haematol 2017 Apr;177(2):221-225 PMID: 28387460 SCOPUS ID: 2-s2.0-85017133877 04/08/2017 62 Citations

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017 8 Citations

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 PMID: 28159578 SCOPUS ID: 2-s2.0-85011032026 02/06/2017 20 Citations

Allogeneic hematopoietic transplant in multiple myeloma (Hari P, Dhakal B) Clinical Manual of Blood and Bone Marrow Transplantation 1 January 2017:207-213 SCOPUS ID: 2-s2.0-85218371407 01/01/2017

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. (Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P) Case Rep Hematol 2016;2016:2389038 PMID: 27843657 PMCID: PMC5097796 11/16/2016

Recent advances in understanding multiple myeloma. (Dhakal B, Girnius S, Hari P) F1000Res 2016;5 PMID: 27610224 PMCID: PMC4995679 09/10/2016

Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 SCOPUS ID: 2-s2.0-84992043960 06/28/2016 8 Citations

Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. (Krishnan A, Vij R, Keller J, Dhakal B, Hari P) Am Soc Clin Oncol Educ Book 2016;35:210-21 PMID: 27249701 SCOPUS ID: 2-s2.0-84994889855 06/02/2016 7 Citations

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016 22 Citations

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 SCOPUS ID: 2-s2.0-85011094757 03/05/2016 14 Citations

Allogeneic stem cell transplantation for multiple myeloma: is there a future? (Dhakal B, Vesole DH, Hari PN) Bone Marrow Transplant 2016 Apr;51(4):492-500 PMID: 26726943 SCOPUS ID: 2-s2.0-84953338728 01/05/2016 54 Citations

Recent advances in understanding multiple myeloma. (Dhakal B, Girnius S, Hari P) F1000research 2016;5 SCOPUS ID: 2-s2.0-85010977523 01/01/2016 12 Citations

Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. (Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A) Bone Marrow Transplant 2016 Feb;51(2):297-9 PMID: 26457907 PMCID: PMC4956087 SCOPUS ID: 2-s2.0-84956915976 10/13/2015 10 Citations

Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. (Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B) Bone Marrow Transplant 2016 Feb;51(2):300-2 PMID: 26457913 SCOPUS ID: 2-s2.0-84956921726 10/13/2015 33 Citations

Localized lymph node light chain amyloidosis. (Dhakal B, Harrington AM, Stadler ME, D'Souza A) Case Rep Hematol 2015;2015:816565 PMID: 25922771 PMCID: PMC4398934 04/30/2015

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 SCOPUS ID: 2-s2.0-84926418285 01/27/2015 7 Citations

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 SCOPUS ID: 2-s2.0-84930383567 11/12/2014 12 Citations

Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 SCOPUS ID: 2-s2.0-84912142377 08/12/2014 26 Citations

Death during an asthma exacerbation in an adult with sickle cell disease: an autopsy case study. (Dhakal B, Giese K, Santo-Thomas L, Field JJ) Am J Hematol 2013 Sep;88(9):824 PMID: 23720156 SCOPUS ID: 2-s2.0-84882680165 05/31/2013 5 Citations

Morbidities of lung cancer surgery in obese patients. (Dhakal B, Eastwood D, Sukumaran S, Hassler G, Tisol W, Gasparri M, Choong N, Santana-Davila R) J Thorac Cardiovasc Surg 2013 Aug;146(2):379-84 PMID: 23618391 PMCID: PMC4986510 SCOPUS ID: 2-s2.0-84880315353 04/27/2013 29 Citations

Pemetrexed induced pneumonitis. (Dhakal B, Singh V, Shrestha A, Rao A, Choong N) Clin Pract 2011 Sep 28;1(4):e106 PMID: 24765347 PMCID: PMC3981441 09/28/2011

Resolving diagnostic uncertainty in initially poorly localizable fevers: a prospective study. (Biswas R, Dhakal B, Das RN, Shetty KJ) Int J Clin Pract 2004 Jan;58(1):26-8 PMID: 14994967 SCOPUS ID: 2-s2.0-1342305134 03/05/2004 7 Citations

Last update: 05/09/2026

© 2026 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Binod Dhakal MBBS, MD

Associate Professor

Publications (192)